Regeneron and Sanofi’s Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. read more ​  ​Regeneron and Sanofi’s Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. read more 

US retail sales in October surpass expectations with a 0.4% increase, the highest since July 2024. This signals resilience in consumer spending before the presidential election. read more ​  ​US retail sales in October surpass expectations with a 0.4% increase, the highest since July 2024. This signals resilience in consumer spending before the presidential election.

Altria Group is “undervalued,” Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. read more ​  ​Altria Group is “undervalued,” Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. read more 

read more ​  ​read more 

read more ​  ​read more 

read more ​  ​read more 

​Post Content  Read More